Compounds > nimbolide
Page last updated: 2024-08-26

nimbolide and Pancreatic Neoplasms

nimbolide has been researched along with Pancreatic Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Behera, S; Dixit, A; Kumar, S; Mohapatra, P; Sahoo, SK; Singh, D1
Hussain, MD; Patra, A; Satpathy, S1
Attwood, K; Balachandar, S; Chandra, D; Chaudhary, AK; Hochwald, S; Inigo, JR; Kumar, R; Kumar, S; O'Malley, J; Wang, J; Wang, X; Yadav, N1
Arumugam, A; Bonkoungou, S; Camacho, F; Dwivedi, Ak; Gonzalez, E; Gonzalez, V; Lakshmanaswamy, R; Medel, J; Nandy, S; Narayan, M; Ortega, A; Subramani, R1
Aggarwal, BB; Gupta, SC; Hema, PS; Nair, M; Park, B; Phromnoi, K; Reuter, S1

Other Studies

5 other study(ies) available for nimbolide and Pancreatic Neoplasms

ArticleYear
Nimbolide-encapsulated PLGA nanoparticles induces Mesenchymal-to-Epithelial Transition by dual inhibition of AKT and mTOR in pancreatic cancer stem cells.
    Toxicology in vitro : an international journal published in association with BIBRA, 2022, Volume: 79

    Topics: Cell Line, Tumor; Epithelial-Mesenchymal Transition; Humans; Limonins; Molecular Docking Simulation; Nanoparticles; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Binding; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases

2022
Nanodelivery and anticancer effect of a limonoid, nimbolide, in breast and pancreatic cancer cells.
    International journal of nanomedicine, 2019, Volume: 14

    Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Cryoprotective Agents; Drug Delivery Systems; Drug Liberation; Female; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Limonins; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Static Electricity

2019
Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.
    Cancer letters, 2018, 01-28, Volume: 413

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase Inhibitors; Cell Line, Tumor; Cell Movement; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Hyaluronan Receptors; Limonins; Mitochondria; Mutation; Neoplastic Stem Cells; Pancreatic Neoplasms; Reactive Oxygen Species; Time Factors; Tumor Suppressor Protein p53

2018
Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition.
    Scientific reports, 2016, Jan-25, Volume: 6

    Topics: Adenine; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Limonins; MAP Kinase Signaling System; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species

2016
Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax.
    The Journal of biological chemistry, 2011, Jan-14, Volume: 286, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Colonic Neoplasms; Extracellular Signal-Regulated MAP Kinases; HCT116 Cells; HT29 Cells; Humans; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Limonins; Lung Neoplasms; Multiple Myeloma; Pancreatic Neoplasms; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53

2011